In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on FibroGen (FGEN), with a price target of $72.00. The company’s shares closed last Tuesday at $35.44.
According to TipRanks.com, Yang has 0 stars on 0-5 stars ranking scale with an average return of -8.6% and a 34.3% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Sarepta Therapeutics, and Revance Therapeutics.
Currently, the analyst consensus on FibroGen is a Moderate Buy with an average price target of $48.83.
See today’s analyst top recommended stocks >>
Based on FibroGen’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $24.4 million and GAAP net loss of $78.35 million. In comparison, last year the company earned revenue of $23.86 million and had a GAAP net loss of $45.41 million.
Based on the recent corporate insider activity of 72 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of FGEN in relation to earlier this year. Most recently, in March 2020, Thomas Kearns, a Director at FGEN sold 18,000 shares for a total of $417,060.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
FibroGen, Inc. engages in the discovery, development, and commercialization of therapeutics. It focuses on hypoxia-inducible factor and connective tissue growth factor biology to develop innovative medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
